Atlas FDA

SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System, SYNERGY XD Everolimus-Eluting Platinum Chromium Coro

FDA premarket approval P150003/S090 · decided 2023-03-02

Approval details

PMA number
P150003
Supplement
S090
Supplement type
Real-Time Process
Supplement reason
Change Design/Components/Specifications/Material
Trade name
SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System, SYNERGY XD Everolimus-Eluting Platinum Chromium Coro
Generic name
Coronary drug-eluting stent
Applicant
Boston Scientific Corporation
Date received
2022-12-07
Decision date
2023-03-02
Days to decision
85 days
Decision code
APPR
Product code
NIQ
Advisory committee
Cardiovascular
Expedited review
No
Location
Maple Grove, MN
Statement
Approval for the introduction of an alternative resin material (ReZilok Rx 101) supplied by existing BSC-approved supplier Compounding Solutions.

Class III intelligence, same tools

PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.

510(k) clearances by this applicant

RecordFirmDate
TheraSphere 360™ Y-90 Management Platform (K262462)Boston Scientific Corporation2026-07-24
FARADRIVE™ Steerable Sheath (M004PF21M402) (K262165)Boston Scientific Corporation2026-07-24
OBSIDIO Conformable Embolic (K261488)Boston Scientific Corporation2026-07-24
WallFlex Esophageal Stent System;Agile Esophageal Over-the-Wire (OTW) Stent System (K261978)Boston Scientific Corporation2026-07-10
RIVOS™ EUS Access Device (M00553900) (K260428)Boston Scientific Corporation2026-06-17
MOSES Raydar™ (K260100)Boston Scientific Corporation2026-05-18
TruSelect™ 2.6 Microcatheter (K260771)Boston Scientific Corporation2026-05-15
Asurys Fluid Management System (K251273)Boston Scientific Corporation2026-03-27